This concept is supported by animal model studies showing that and ASK1 inhibition reduces kidney injury associated with diabetes or ischemic injury, as well as clinical trials demonstrating that ASK1 inhibitor protects patients from DKD [19]. Here, MAP3K5 is linked to diabetes mellitus.